BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31870630)

  • 1. Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.
    Sagel SD; Wagner BD; Ziady A; Kelley T; Clancy JP; Narvaez-Rivas M; Pilewski J; Joseloff E; Sha W; Zelnick L; Setchell KDR; Heltshe SL; Muhlebach MS
    J Cyst Fibros; 2020 Jul; 19(4):632-640. PubMed ID: 31870630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.
    Ratjen F; Saiman L; Mayer-Hamblett N; Lands LC; Kloster M; Thompson V; Emmett P; Marshall B; Accurso F; Sagel S; Anstead M
    Chest; 2012 Nov; 142(5):1259-1266. PubMed ID: 22595153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The determinants of survival among adults with cystic fibrosis-a cohort study.
    Durda-Masny M; Goździk-Spychalska J; John A; Czaiński W; Stróżewska W; Pawłowska N; Wlizło J; Batura-Gabryel H; Szwed A
    J Physiol Anthropol; 2021 Nov; 40(1):19. PubMed ID: 34749804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Epididymis Protein 4: A Novel Serum Inflammatory Biomarker in Cystic Fibrosis.
    Nagy B; Nagy B; Fila L; Clarke LA; Gönczy F; Bede O; Nagy D; Újhelyi R; Szabó Á; Anghelyi A; Major M; Bene Z; Fejes Z; Antal-Szalmás P; Bhattoa HP; Balla G; Kappelmayer J; Amaral MD; Macek M; Balogh I
    Chest; 2016 Sep; 150(3):661-72. PubMed ID: 27105680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.
    Levy H; Kalish LA; Cannon CL; García KC; Gerard C; Goldmann D; Pier GB; Weiss ST; Colin AA
    Pediatr Pulmonol; 2008 May; 43(5):463-71. PubMed ID: 18361452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.
    Pittman JE; Noah H; Calloway HE; Davis SD; Leigh MW; Drumm M; Sagel SD; Accurso FJ; Knowles MR; Sontag MK
    PLoS One; 2017; 12(5):e0177215. PubMed ID: 28505188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening.
    Munck A; Bourmaud A; Bellon G; Picq P; Farrell PM;
    Pediatr Pulmonol; 2020 Apr; 55(4):918-928. PubMed ID: 31916691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function.
    Kosamo S; Hisert KB; Dmyterko V; Nguyen C; Black RA; Holden TD; Radella F; Cotten PA; Goss CH; Aitken ML; Wurfel MM
    J Cyst Fibros; 2020 Jul; 19(4):608-613. PubMed ID: 31813753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function.
    Masood A; Jacob M; Gu X; Abdel Jabar M; Benabdelkamel H; Nizami I; Li L; Dasouki M; Abdel Rahman AM
    Metabolomics; 2021 Jan; 17(1):4. PubMed ID: 33394183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
    Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL1B polymorphisms modulate cystic fibrosis lung disease.
    Levy H; Murphy A; Zou F; Gerard C; Klanderman B; Schuemann B; Lazarus R; García KC; Celedón JC; Drumm M; Dahmer M; Quasney M; Schneck K; Reske M; Knowles MR; Pier GB; Lange C; Weiss ST
    Pediatr Pulmonol; 2009 Jun; 44(6):580-93. PubMed ID: 19431193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in lung function and nutritional decline in cystic fibrosis by genotype: An analysis of the Canadian cystic fibrosis registry.
    Leung GJ; Cho TJ; Kovesi T; Hamid JS; Radhakrishnan D
    J Cyst Fibros; 2020 Mar; 19(2):255-261. PubMed ID: 31253541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe disease in Cystic Fibrosis and fecal calprotectin levels.
    Parisi GF; Papale M; Rotolo N; Aloisio D; Tardino L; Scuderi MG; Di Benedetto V; Nenna R; Midulla F; Leonardi S
    Immunobiology; 2017 Mar; 222(3):582-586. PubMed ID: 28012584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating CRP and calprotectin to diagnose CF pulmonary exacerbations.
    Jung D; Dong K; Jang J; Lam GY; Wilcox PG; Quon BS
    J Cyst Fibros; 2021 Jan; 20(1):46-49. PubMed ID: 32475777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.
    Stotland PK; Radzioch D; Stevenson MM
    Pediatr Pulmonol; 2000 Nov; 30(5):413-24. PubMed ID: 11064433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.
    Horsley AR; Davies JC; Gray RD; Macleod KA; Donovan J; Aziz ZA; Bell NJ; Rainer M; Mt-Isa S; Voase N; Dewar MH; Saunders C; Gibson JS; Parra-Leiton J; Larsen MD; Jeswiet S; Soussi S; Bakar Y; Meister MG; Tyler P; Doherty A; Hansell DM; Ashby D; Hyde SC; Gill DR; Greening AP; Porteous DJ; Innes JA; Boyd AC; Griesenbach U; Cunningham S; Alton EW
    Thorax; 2013 Jun; 68(6):532-9. PubMed ID: 23396354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical expression of cystic fibrosis in a large cohort of Italian siblings.
    Terlizzi V; Lucarelli M; Salvatore D; Angioni A; Bisogno A; Braggion C; Buzzetti R; Carnovale V; Casciaro R; Castaldo G; Cirilli N; Collura M; Colombo C; Di Lullo AM; Elce A; Lucidi V; Madarena E; Padoan R; Quattrucci S; Raia V; Seia M; Termini L; Zarrilli F
    BMC Pulm Med; 2018 Dec; 18(1):196. PubMed ID: 30577776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV
    Nagy B; Bene Z; Fejes Z; Heltshe SL; Reid D; Ronan NJ; McCarthy Y; Smith D; Nagy A; Joseloff E; Balla G; Kappelmayer J; Macek M; Bell SC; Plant BJ; Amaral MD; Balogh I
    J Cyst Fibros; 2019 Mar; 18(2):271-277. PubMed ID: 30268371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.